Research analysts at StockNews.com started coverage on shares of Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) in a research note issued on Sunday. The brokerage set a “sell” rating on the basic materials company’s stock.
Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of Arcadia Biosciences in a research note on Wednesday, August 21st.
Check Out Our Latest Report on RKDA
Arcadia Biosciences Price Performance
Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) last posted its earnings results on Tuesday, August 13th. The basic materials company reported $0.78 earnings per share for the quarter, missing analysts’ consensus estimates of $1.27 by ($0.49). Arcadia Biosciences had a negative net margin of 127.29% and a negative return on equity of 57.51%. The business had revenue of $1.31 million during the quarter, compared to analysts’ expectations of $0.95 million. During the same period last year, the business posted ($2.64) earnings per share. On average, analysts anticipate that Arcadia Biosciences will post -1.7 EPS for the current fiscal year.
About Arcadia Biosciences
Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.
Recommended Stories
- Five stocks we like better than Arcadia Biosciences
- 3 Warren Buffett Stocks to Buy Now
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- What is the Australian Securities Exchange (ASX)
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- What is the Hang Seng index?
- RPM International Thrives in Rate-Cut Driven Construction Rally
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.